BioCryst Pharmaceuticals, Inc. provided earnings guidance for the full year 2022. For the period, the company expected full year 2022 net ORLADEYO revenue to be between $255 million and $265 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.115 USD | -2.76% | +11.27% | -15.11% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.11% | 1.09B | |
+3.80% | 106B | |
+7.02% | 23.47B | |
-14.62% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-9.87% | 16.78B | |
+5.78% | 14.41B | |
+35.22% | 12.86B | |
+321.33% | 8.78B |
- Stock Market
- Equities
- BCRX Stock
- News BioCryst Pharmaceuticals, Inc.
- Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022